Literature DB >> 11750969

Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis.

Andrzej Cyrkowicz1.   

Abstract

OBJECTIVES: To compare the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing gynecological operations without low molecular weight heparin (LMWH) prophylaxis and those receiving such prophylaxis.
DESIGN: Retrospective, hospital record-based study.
MATERIAL AND METHODS: About 1785 consecutive patients without LMWH prophylaxis and 1871 ones treated with nadroparin (Fraxiparine) 7500ICU s.c. 2h before the operation and repeated daily for 5-7 days or until the patient was fully mobile. DVT was diagnosed on the basis of clinical symptoms and ultrasound examination, and PE on clinical symptoms, gasometric data, electrocardiography and chest X-ray.
RESULTS: Among the patients without prophylaxis, four cases of PE occurred (0.22%), two fatal (0.11%), 13 cases of proximal DVT (0.72%) and 41 distal DVT complications (2.3%). In LMWH, group 3 proximal DVT (0.16%) and 18 distal DVT (0.96%) developed but there were no clinically expressed pulmonary embolism. According to the Fisher's exact test, the difference between the complications in the analyzed groups is significant P<0.05.
CONCLUSION: The perioperative applying of LMWH to prevent DVT in the patients operated on gynecologically is effective.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11750969     DOI: 10.1016/s0301-2115(01)00482-1

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

Review 1.  Prevention of venous thromboembolism in gynecologic oncology surgery.

Authors:  Emma L Barber; Daniel L Clarke-Pearson
Journal:  Gynecol Oncol       Date:  2016-11-25       Impact factor: 5.482

2.  Analysis of deep venous thrombosis after Gynecological surgery: A clinical study of 498 cases.

Authors:  Lihua Zhang; Xiancui Liu; Yunxia Xue
Journal:  Pak J Med Sci       Date:  2015 Mar-Apr       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.